Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD
We retrospectively analyzed clinical outcomes of patients aged 18–59 with cytogenetically normal AML (CN-AML) and mutations in the FLT3 receptor according to type of postremission therapy. Specifically, we compared the outcomes of patients who underwent autologous SCT versus consolidation chemothera...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2011-07, Vol.86 (7), p.625-627 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 627 |
|---|---|
| container_issue | 7 |
| container_start_page | 625 |
| container_title | American journal of hematology |
| container_volume | 86 |
| creator | Singh, Harshabad Werner, Lillian L. Asali, Salma DeAngelo, Daniel J. Ballen, Karen K. Amrein, Philip C. Wadleigh, Martha Galinsky, Ilene Wolpin, Brian Pidala, Joseph Neuberg, Donna S. Fox, Edward A. Stone, Richard M. Attar, Eyal C. |
| description | We retrospectively analyzed clinical outcomes of patients aged 18–59 with cytogenetically normal AML (CN-AML) and mutations in the FLT3 receptor according to type of postremission therapy. Specifically, we compared the outcomes of patients who underwent autologous SCT versus consolidation chemotherapy. There were 37 patients with an ITD mutation (7 also had a TKD mutation) and 19 patients with an isolated TKD mutation at diagnosis. In all, patients with an isolated TKD (n=16) had an improved DFS and OS (p=.031 and .014, respectively) compared to ITD patients (n=21). For individuals with an isolated TKD mutation, survival outcomes were similar irrespective of the type of postremission therapy (n=7 for SCT and 9 for chemotherapy) (p=0.97 and 0.082, respectively). However, ITD positive patients who underwent an SCT in CR1 (n=10) had an improved DFS but similar OS compared to those who received consolidation chemotherapy (n=11) (p=.05 and .27). These results suggest that high dose chemotherapy with autologous SCT may be a reasonable therapeutic choice over consolidation chemotherapy for young CN-AML patients with a FLT3ITD mutation. |
| doi_str_mv | 10.1002/ajh.22041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3495174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3276158041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4721-2f2f2d25b4dc22724e651e0de87790c4eb327ba28ac5856682b0dbb6c43c63e33</originalsourceid><addsrcrecordid>eNp1kstu1DAUhiMEokNhwQsgSwhBF9PajpM4G6TRQGnRAJthbTnOyYwHxw620yo7HoH34K14ElxmKBcJeWHr-NN_bn-WPSb4lGBMz-Rue0opZuRONiO4Lue8LOjdbIbzkqQ3ro-yByHsMCaEcXw_O6Kk5KTi1Sz7tnT9IL0OziLXITlGZ9zGjQGFCD1SYAyKXtowGGmjjDpxV-BDApSzwRnd7oNqC72LW_BymFDnPBpSHGwM6FrHLVJTdBuwELWSxkzIOt9Lg6QaI6B-AuN0iwyMn6DXEr1Yvv_-5evi3eoESdui89U6v1y_epjd66QJ8OhwH2cfz1-vlxfz1Yc3l8vFaq5YRcmcdum0tGhYqyitKIOyIIBb4FVVY8WgyWnVSMqlKnhRlpw2uG2aUrFclTnk-XH2cq87jE0PrUpdeGnE4HUv_SSc1OLvH6u3YuOuRM7qglQsCTw_CHj3eYQQRa_DzSilhTRawVNReckYSeTTf8idG71N3QlSkJIVtGJ1ok72lPIuBA_dbS0EixsHiOQA8dMBiX3yZ_G35K-VJ-DZAZAh7aJLy1U6_OYY5YwzmrizPXetDUz_zygWby_2qX8Ay-jMYw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1516452749</pqid></control><display><type>article</type><title>Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Singh, Harshabad ; Werner, Lillian L. ; Asali, Salma ; DeAngelo, Daniel J. ; Ballen, Karen K. ; Amrein, Philip C. ; Wadleigh, Martha ; Galinsky, Ilene ; Wolpin, Brian ; Pidala, Joseph ; Neuberg, Donna S. ; Fox, Edward A. ; Stone, Richard M. ; Attar, Eyal C.</creator><creatorcontrib>Singh, Harshabad ; Werner, Lillian L. ; Asali, Salma ; DeAngelo, Daniel J. ; Ballen, Karen K. ; Amrein, Philip C. ; Wadleigh, Martha ; Galinsky, Ilene ; Wolpin, Brian ; Pidala, Joseph ; Neuberg, Donna S. ; Fox, Edward A. ; Stone, Richard M. ; Attar, Eyal C.</creatorcontrib><description>We retrospectively analyzed clinical outcomes of patients aged 18–59 with cytogenetically normal AML (CN-AML) and mutations in the FLT3 receptor according to type of postremission therapy. Specifically, we compared the outcomes of patients who underwent autologous SCT versus consolidation chemotherapy. There were 37 patients with an ITD mutation (7 also had a TKD mutation) and 19 patients with an isolated TKD mutation at diagnosis. In all, patients with an isolated TKD (n=16) had an improved DFS and OS (p=.031 and .014, respectively) compared to ITD patients (n=21). For individuals with an isolated TKD mutation, survival outcomes were similar irrespective of the type of postremission therapy (n=7 for SCT and 9 for chemotherapy) (p=0.97 and 0.082, respectively). However, ITD positive patients who underwent an SCT in CR1 (n=10) had an improved DFS but similar OS compared to those who received consolidation chemotherapy (n=11) (p=.05 and .27). These results suggest that high dose chemotherapy with autologous SCT may be a reasonable therapeutic choice over consolidation chemotherapy for young CN-AML patients with a FLT3ITD mutation.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.22041</identifier><identifier>PMID: 21681787</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Biological and medical sciences ; Disease-Free Survival ; Female ; fms-Like Tyrosine Kinase 3 - genetics ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - mortality ; Leukemia, Myeloid, Acute - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Mutation ; Stem Cell Transplantation ; Survival Rate ; Transplantation, Autologous</subject><ispartof>American journal of hematology, 2011-07, Vol.86 (7), p.625-627</ispartof><rights>Copyright © 2011 Wiley‐Liss, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4721-2f2f2d25b4dc22724e651e0de87790c4eb327ba28ac5856682b0dbb6c43c63e33</citedby><cites>FETCH-LOGICAL-c4721-2f2f2d25b4dc22724e651e0de87790c4eb327ba28ac5856682b0dbb6c43c63e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.22041$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.22041$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,778,782,883,1414,1430,27913,27914,45563,45564,46398,46822</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24284842$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21681787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Harshabad</creatorcontrib><creatorcontrib>Werner, Lillian L.</creatorcontrib><creatorcontrib>Asali, Salma</creatorcontrib><creatorcontrib>DeAngelo, Daniel J.</creatorcontrib><creatorcontrib>Ballen, Karen K.</creatorcontrib><creatorcontrib>Amrein, Philip C.</creatorcontrib><creatorcontrib>Wadleigh, Martha</creatorcontrib><creatorcontrib>Galinsky, Ilene</creatorcontrib><creatorcontrib>Wolpin, Brian</creatorcontrib><creatorcontrib>Pidala, Joseph</creatorcontrib><creatorcontrib>Neuberg, Donna S.</creatorcontrib><creatorcontrib>Fox, Edward A.</creatorcontrib><creatorcontrib>Stone, Richard M.</creatorcontrib><creatorcontrib>Attar, Eyal C.</creatorcontrib><title>Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>We retrospectively analyzed clinical outcomes of patients aged 18–59 with cytogenetically normal AML (CN-AML) and mutations in the FLT3 receptor according to type of postremission therapy. Specifically, we compared the outcomes of patients who underwent autologous SCT versus consolidation chemotherapy. There were 37 patients with an ITD mutation (7 also had a TKD mutation) and 19 patients with an isolated TKD mutation at diagnosis. In all, patients with an isolated TKD (n=16) had an improved DFS and OS (p=.031 and .014, respectively) compared to ITD patients (n=21). For individuals with an isolated TKD mutation, survival outcomes were similar irrespective of the type of postremission therapy (n=7 for SCT and 9 for chemotherapy) (p=0.97 and 0.082, respectively). However, ITD positive patients who underwent an SCT in CR1 (n=10) had an improved DFS but similar OS compared to those who received consolidation chemotherapy (n=11) (p=.05 and .27). These results suggest that high dose chemotherapy with autologous SCT may be a reasonable therapeutic choice over consolidation chemotherapy for young CN-AML patients with a FLT3ITD mutation.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>fms-Like Tyrosine Kinase 3 - genetics</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Stem Cell Transplantation</subject><subject>Survival Rate</subject><subject>Transplantation, Autologous</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kstu1DAUhiMEokNhwQsgSwhBF9PajpM4G6TRQGnRAJthbTnOyYwHxw620yo7HoH34K14ElxmKBcJeWHr-NN_bn-WPSb4lGBMz-Rue0opZuRONiO4Lue8LOjdbIbzkqQ3ro-yByHsMCaEcXw_O6Kk5KTi1Sz7tnT9IL0OziLXITlGZ9zGjQGFCD1SYAyKXtowGGmjjDpxV-BDApSzwRnd7oNqC72LW_BymFDnPBpSHGwM6FrHLVJTdBuwELWSxkzIOt9Lg6QaI6B-AuN0iwyMn6DXEr1Yvv_-5evi3eoESdui89U6v1y_epjd66QJ8OhwH2cfz1-vlxfz1Yc3l8vFaq5YRcmcdum0tGhYqyitKIOyIIBb4FVVY8WgyWnVSMqlKnhRlpw2uG2aUrFclTnk-XH2cq87jE0PrUpdeGnE4HUv_SSc1OLvH6u3YuOuRM7qglQsCTw_CHj3eYQQRa_DzSilhTRawVNReckYSeTTf8idG71N3QlSkJIVtGJ1ok72lPIuBA_dbS0EixsHiOQA8dMBiX3yZ_G35K-VJ-DZAZAh7aJLy1U6_OYY5YwzmrizPXetDUz_zygWby_2qX8Ay-jMYw</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Singh, Harshabad</creator><creator>Werner, Lillian L.</creator><creator>Asali, Salma</creator><creator>DeAngelo, Daniel J.</creator><creator>Ballen, Karen K.</creator><creator>Amrein, Philip C.</creator><creator>Wadleigh, Martha</creator><creator>Galinsky, Ilene</creator><creator>Wolpin, Brian</creator><creator>Pidala, Joseph</creator><creator>Neuberg, Donna S.</creator><creator>Fox, Edward A.</creator><creator>Stone, Richard M.</creator><creator>Attar, Eyal C.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201107</creationdate><title>Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD</title><author>Singh, Harshabad ; Werner, Lillian L. ; Asali, Salma ; DeAngelo, Daniel J. ; Ballen, Karen K. ; Amrein, Philip C. ; Wadleigh, Martha ; Galinsky, Ilene ; Wolpin, Brian ; Pidala, Joseph ; Neuberg, Donna S. ; Fox, Edward A. ; Stone, Richard M. ; Attar, Eyal C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4721-2f2f2d25b4dc22724e651e0de87790c4eb327ba28ac5856682b0dbb6c43c63e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>fms-Like Tyrosine Kinase 3 - genetics</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Stem Cell Transplantation</topic><topic>Survival Rate</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Harshabad</creatorcontrib><creatorcontrib>Werner, Lillian L.</creatorcontrib><creatorcontrib>Asali, Salma</creatorcontrib><creatorcontrib>DeAngelo, Daniel J.</creatorcontrib><creatorcontrib>Ballen, Karen K.</creatorcontrib><creatorcontrib>Amrein, Philip C.</creatorcontrib><creatorcontrib>Wadleigh, Martha</creatorcontrib><creatorcontrib>Galinsky, Ilene</creatorcontrib><creatorcontrib>Wolpin, Brian</creatorcontrib><creatorcontrib>Pidala, Joseph</creatorcontrib><creatorcontrib>Neuberg, Donna S.</creatorcontrib><creatorcontrib>Fox, Edward A.</creatorcontrib><creatorcontrib>Stone, Richard M.</creatorcontrib><creatorcontrib>Attar, Eyal C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Harshabad</au><au>Werner, Lillian L.</au><au>Asali, Salma</au><au>DeAngelo, Daniel J.</au><au>Ballen, Karen K.</au><au>Amrein, Philip C.</au><au>Wadleigh, Martha</au><au>Galinsky, Ilene</au><au>Wolpin, Brian</au><au>Pidala, Joseph</au><au>Neuberg, Donna S.</au><au>Fox, Edward A.</au><au>Stone, Richard M.</au><au>Attar, Eyal C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2011-07</date><risdate>2011</risdate><volume>86</volume><issue>7</issue><spage>625</spage><epage>627</epage><pages>625-627</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>We retrospectively analyzed clinical outcomes of patients aged 18–59 with cytogenetically normal AML (CN-AML) and mutations in the FLT3 receptor according to type of postremission therapy. Specifically, we compared the outcomes of patients who underwent autologous SCT versus consolidation chemotherapy. There were 37 patients with an ITD mutation (7 also had a TKD mutation) and 19 patients with an isolated TKD mutation at diagnosis. In all, patients with an isolated TKD (n=16) had an improved DFS and OS (p=.031 and .014, respectively) compared to ITD patients (n=21). For individuals with an isolated TKD mutation, survival outcomes were similar irrespective of the type of postremission therapy (n=7 for SCT and 9 for chemotherapy) (p=0.97 and 0.082, respectively). However, ITD positive patients who underwent an SCT in CR1 (n=10) had an improved DFS but similar OS compared to those who received consolidation chemotherapy (n=11) (p=.05 and .27). These results suggest that high dose chemotherapy with autologous SCT may be a reasonable therapeutic choice over consolidation chemotherapy for young CN-AML patients with a FLT3ITD mutation.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21681787</pmid><doi>10.1002/ajh.22041</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2011-07, Vol.86 (7), p.625-627 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3495174 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content |
| subjects | Adult Biological and medical sciences Disease-Free Survival Female fms-Like Tyrosine Kinase 3 - genetics Hematologic and hematopoietic diseases Hematology Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Mutation Stem Cell Transplantation Survival Rate Transplantation, Autologous |
| title | Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN‐AML) and FLT3ITD |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T07%3A53%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20autologous%20stem%20cell%20transplantation%20versus%20consolidation%20chemotherapy%20for%20patients%20with%20cytogenetically%20normal%20acute%20myeloid%20leukemia%20(CN%E2%80%90AML)%20and%20FLT3ITD&rft.jtitle=American%20journal%20of%20hematology&rft.au=Singh,%20Harshabad&rft.date=2011-07&rft.volume=86&rft.issue=7&rft.spage=625&rft.epage=627&rft.pages=625-627&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.22041&rft_dat=%3Cproquest_pubme%3E3276158041%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1516452749&rft_id=info:pmid/21681787&rfr_iscdi=true |